Comparison

Cagrilintide vs. Semaglutid

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Cagrilintide

Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Cagrilintide	Semaglutid
Switzerland	—	Prescription
Germany	Unapproved	Prescription
DK	Unapproved	—
United States	Unapproved	Prescription

Full entries

Frequently asked questions

What is the difference between Cagrilintide and Semaglutid?: Cagrilintide is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cagrilintide or Semaglutid?: The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cagrilintide and Semaglutid in Germany and the United States?: Germany: Cagrilintide — Unapproved, Semaglutid — Prescription. United States: Cagrilintide — Unapproved, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Cagrilintide

Semaglutid

Switzerland

—

Prescription

Germany

Unapproved

Prescription

Unapproved

—

United States

Unapproved

Prescription

Frequently asked questions

What is the difference between Cagrilintide and Semaglutid?

Cagrilintide is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cagrilintide or Semaglutid?

The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cagrilintide and Semaglutid in Germany and the United States?

Germany: Cagrilintide — Unapproved, Semaglutid — Prescription. United States: Cagrilintide — Unapproved, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.